DLL3 and small cell lung carcinoma: In the Phase II TRINITY study (protocol number: NCT02674568), rovalpituzumab tesirine demonstrated modest clinical activity among the 339 pretreated patients with SCLC, and the response rate for DLL3-positive patients was 13.2% [95].